Mylan Inc. has launched risedronate sodium tablets (150 mg), indicated for the treatment and prevention of osteoporosis in postmenopausal women.


Mylan, risedronate sodium tablets, generic version of Actonel, Warner Chilcott, osteoporosis in postmenopausal women








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan releases generic Actonel

June 12th, 2014

PITTSBURGH – Mylan Inc. has launched risedronate sodium tablets (150 mg), indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Mylan said Wednesday that it has received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for the product, a generic version of Actonel tablets from Warner Chilcott.

Risedronate slows bone loss and increases bone mass, helping to prevent bone fractures related to osteoporosis.

According to IMS Health data reported by Mylan, risedronate sodium tablets (150 mg) had U.S. sales of approximately $171.6 million for the 12 months ended March 31.

 

 

Advertisement